18 April 2012 May 2012 Pharmaceutical Schedule Dispatch This document is provided to pharmacists as an early notification of the changes to be announced in the May 2012 Update to the Pharmaceutical Schedule. Please notify PHARMAC (0800 66 00 50) to change or remove your contact details. New listings Bisoprolol fumarate (Bosvate) tab 2.5 mg (p’code 2392844), 5 mg (p’code 2392852) and 10 mg (p’code 2392860) Propylthiouracil (PTU) tab 50 mg – Special Authority – Retail Pharmacy (p’code 2010526) (section 29) Brimonidine tartrate (Arrow-Brimonidine) eye drops 0.2%, 5 ml OP (p’code 2396513)
Changes to restrictions Sodium chloride (Biomed) inj 23.4%, 20 ml - addition of oral standard formula for treatment of hyponatraemia Ciclopiroxolamine – amend chemical name to ciclopirox olamine Sunitinib (Sutent) – amended Special Authority Lapatinib (Tykerb) – amend therapeutic subgroup to protein-tyrosine kinase inhibitors Glaucoma preparations – removal of Prescribing Guidelines Brinzolamide (Azopt) eye drops 1% – addition of stat dispensing Bimatoprost (Lumigan) eye drops 0.03% – addition of stat dispensing Latanoprost (Hysite) eye drops 50 µg per ml, 2.5 ml – addition of stat dispensing Travoprost (Travatan) eye drops 0.0004% – addition of stat dispensing Brimonidine tartrate with timolol maleate (Combigan) eye drops 0.2% with timolol maleate 0.5% – addition of stat dispensing Decreased subsidy
Chemical Presentation Fully subsidised brands Partially subsidised brands Actigall Ursosan* (Cap 250 mg) Metoprolol - AFT CR Myloc CR* Betaloc CR* Lopresor Lopresor Slow-Lopresor Betaloc Multichem* PSM Dalacin C Clindamycin ABM* Rizamelt* Octreotide MaxRx*
Ursodeoxycholic acid Metoprolol succinate
Cap 300 mg Tab long-acting 23.75 mg, 47.5 mg, 95 mg and 190 mg Tab 50 mg Tab 100 mg Tab 200 mg Inj 1 mg per ml, 1 ml Oint BP Cap hydrochloride 150 mg Tab orodispersible 10 mg Inj 50 µg per ml, 1 ml, 100 µg per ml, 1 ml and 500 µg per ml, 1 ml Page 1 of 2
Zinc and castor oil Clindamycin Rizatriptan Octreotide (somatostatin analogue)
Maxalt Melt Hospira Sandostatin
A500932 - qA22815
Nebuliser soln, 2.5 mg per 2 ml ampoule Note - there is no subsidy change for this brand.
Increased subsidy Chemical
Tab 10 mg Inj 200 mg per ml, 10 ml
Fully subsidised brands
Motilium Martindale Acetylcysteine
Update on Diabetes Product proposal PHARMAC received 2660 submissions in response to our recent consultation on proposals for diabetes products. At present we are taking the time necessary to carefully work through, and fully understand, the detail of the feedback we have received. We are continuing to seek input and advice from diabetes patients, and other representative groups. We do not yet have a clear view on when a decision will be taken on the proposals; the timeframe will be led by our need to carefully consider the issues raised, and the time needed to make any changes to the proposals that are considered necessary before a decision can be made. PHARMAC Consultations relating to PSA PHARMAC has issued three proposals alongside the PSA as an enabler for the proposed contract. Please note that if the current proposal is altered significantly or does not proceed then we will review our proposals accordingly. Feedback for the proposed changes to the Pharmaceutical Schedule Rules is due this Friday, the 20th April and Review of Dispensing Frequency for Monthly Medicines and Additional Proposals relating to Dispensing Frequency Rule and Access Exemption Rule close on Friday the 26th April. Thanks for feedback received to date.
NB. For further details and magnitude of the above subsidy changes, please consult the online version of the Update to the Pharmaceutical Schedule at: www.pharmac.govt.nz/healthpros/Schedule.
A500932 - qA22815
Page 2 of 2
18 April 2012 May 2012 Pharmaceutical Schedule Dispatch This document is provided to pharmacists as an early notification of the changes to be announced in the May 2012 Update to the Pharmaceutical Schedule. Please notify PHARMAC (0800 66 00 50)…
This text has been extracted from the source PDF document.
Also available as plain text.
Please contact webmaster to discuss alternative format options.